JP Morgan maintains BillionToOne at Overweight, raises price target to $135 from $130

JP Morgan kept its Overweight rating on BillionToOne and increased its price target to $135 from $130, suggesting a 20.1% upside from the Nov 5 close of $112.39.

Original reporting
Published Nov 5, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains BillionToOne at Overweight, raises price target to $135 from $130 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could attract short-term buying interest.

02

Market read

Analyst price‑target increase may prompt modest trading activity.

03

What to watch

No new fundamental data accompanies the target raise.

Relevance 7/10Novelty 7/10Timing: today

Background

JP Morgan raised its price target for BillionToOne, indicating a bullish outlook.

Market effects

Analyst upgrade may lift peer sentiment in the sector.

Limited to US markets where the stock trades.

Minimal global impact.

Counterpoint

Investors may question the sustainability of the new target.

Key entities

  • BillionToOne

    Micro‑cap company covered by JP Morgan's new price target.

Related articles

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.

$BLLNMed

BillionToOne reports Q3 EPS 32c, consensus 30c

BillionToOne (BLLN) reported Q3 EPS of 32 cents, beating the consensus of 30 cents, and revenue of $122.98M, exceeding the consensus of $115.8M. The company highlighted growth, profitability, and clinical validation of its tests. CEO Atay announced the upcoming launch of Northstar Clear. Guggenheim raised its price target to $128 from $125.

$BLLNHighAI 8/10

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,